Blankson Samuel Odarkwei, Rietmeyer Lauriane, Tettey Patrick, Dikroh Liliane, Tornyigah Bernard, Adamou Rafiou, Moussiliou Azizath, Padounou Caroline, Amoussou Annick, Mensah Benedicta Ayiedu, Alao Maroufou J, Awandare Gordon, Ndam Nicaise Tuikue, Roussilhon Christian, Tahar Rachida
MERIT, IRD, Université de Paris Cité, 75006 Paris, France.
West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra LG 54, Ghana.
Diagnostics (Basel). 2023 Jan 31;13(3):528. doi: 10.3390/diagnostics13030528.
Among the barriers to accessing adequate treatment and high-level monitoring for malaria febrile patients is the lack of effective prognostic markers. Neopterin, which is a marker of monocyte/macrophage activation, was found have increased during severe malaria. In this study, we used quantitative ELISA in order to assess the levels of plasma soluble neopterin in 151 patients from a cohort of Beninese children with severe malaria. We evaluated the prognostic accuracy of this molecule in order to predict the outcome of the disease. Our results show that neopterin levels were not significantly different between patients with different forms of severe malaria, including severe non-cerebral malaria (SNCM) and cerebral malaria (CM). However, the levels of this molecule were found to be higher in patients with severe malarial anemia (SMA) among both CM and SNCM cases (-value = 0.02). Additionally, the levels of this molecule were found to be higher in patients who died from these pathologies compared to those who survived among the two clinical groups (-value < 0.0001) and within the same group (-value < 0.0001 for the CM group, -value = 0.0046 for the SNCM group). The AUC-ROC for fatality among all the severe cases was 0.77 with a 95%CI of (0.69-0.85). These results suggest that plasma neopterin levels constitute a potential biomarker for predicting fatality among severe falciparum malaria patients.
对于疟疾发热患者而言,获得充分治疗和高水平监测的障碍之一是缺乏有效的预后标志物。新蝶呤是单核细胞/巨噬细胞活化的标志物,在重症疟疾期间会升高。在本研究中,我们使用定量酶联免疫吸附测定法(ELISA)来评估151名来自贝宁儿童重症疟疾队列患者的血浆可溶性新蝶呤水平。我们评估了该分子预测疾病转归的预后准确性。我们的结果显示,在不同形式的重症疟疾患者中,包括重症非脑型疟疾(SNCM)和脑型疟疾(CM),新蝶呤水平没有显著差异。然而,在CM和SNCM病例中,重症疟疾贫血(SMA)患者的该分子水平更高(P值=0.02)。此外,与两个临床组中存活的患者相比,死于这些疾病的患者该分子水平更高(P值<0.0001),并且在同一组内也是如此(CM组P值<0.0001,SNCM组P值=0.0046)。所有重症病例中死亡的受试者工作特征曲线下面积(AUC-ROC)为0.77,95%置信区间为(0.69-0.85)。这些结果表明,血浆新蝶呤水平构成预测重症恶性疟患者死亡的潜在生物标志物。